GET DAILY SIGNALSRegeneron (REGN) Delivers +36% Revenue Growth in Q3 2026 as Core Products Reach New Highs
Key Takeaways
- Total revenues reached $5,116 million in the third quarter of 2026, a 36% increase from $3,754 million in the prior-year period.
- Diluted earnings per share (EPS) from continuing operations rose to $18.45, while non-GAAP (non-Generally Accepted Accounting Principles) EPS grew approximately 70% year over year.
- Dupixent, EYLEA HD, and Libtayo each set new all-time highs for quarterly net sales for the second consecutive quarter.
- Net income climbed to $1,948.7 million from $1,460 million a year earlier, driven by strong commercial execution and higher collaboration revenue.
- Research and development (R&D) spending increased 22% to $1,795 million, reflecting pipeline advancement and manufacturing activity.
Why the Quarter Matters
Regeneron’s third-quarter 2026 results provide a useful checkpoint for investors tracking whether the company’s broader growth narrative can hold up beyond its leading Dupixent franchise. The period marked a third straight stretch of double-digit gains on both the top and bottom lines, highlighting the resilience of its commercial lineup. Dupixent, reported through partner Sanofi, delivered global net sales of roughly $6.5 billion, while the shift toward EYLEA HD continued to reshape the ophthalmology segment. With ongoing pressure on the older EYLEA franchise and elevated R&D outlays, the report offers a clear view of whether newer assets such as Libtayo and upcoming pipeline readouts can help balance maturing products. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Figures
Regeneron posted total revenues of $5,116 million for the third quarter of 2026, up 36% from $3,754 million a year earlier and ahead of the consensus estimate near $4.54 billion. Net product sales rose 14% to $1,805 million. Sanofi collaboration revenue increased 68% to $2,724 million, helped by a larger profit share from Dupixent and the full repayment of the Sanofi Development Balance earlier in 2026.
Net income reached $1,948.7 million compared with $1,460 million in the same period last year. Diluted EPS from continuing operations came in at $18.45 versus $13.62 a year ago. Non-GAAP EPS grew about 70% year over year to roughly $20, exceeding the analyst consensus near $16.25 according to Yahoo Finance data. From what I see, the product-level results showed a mixed but generally constructive picture. EYLEA HD U.S. net sales surged 62% to $699 million, while legacy EYLEA declined 41% to $400 million as patients moved to the newer formulation. Libtayo global net sales rose 51% to $550 million, with U.S. sales up 81% to $396 million. Dupixent global net sales, reported by Sanofi, hit a record $6.5 billion, increasing 35% at constant currency.
Market Reaction and Investor Sentiment
Heading into the release, sentiment leaned cautiously positive, with focus on whether Dupixent’s momentum could offset continued softness in the legacy EYLEA business. The sizable revenue and EPS beats, paired with record quarterly sales across the three main growth brands, delivered a clear positive surprise relative to expectations. Attention centered on the sustainability of Dupixent’s expansion, the pace of the EYLEA HD transition, and Libtayo’s progress in oncology. The higher R&D spend pointed to continued pipeline investment, which investors generally viewed as a reasonable trade-off given the range of late-stage catalysts.
Forward Outlook and Factors to Watch
Several upcoming events could influence Regeneron’s path. An FDA decision on cemdisiran for generalized myasthenia gravis is expected in November 2026. If approved, it would mark the first siRNA therapy for the condition, offering quarterly subcutaneous dosing. The company also anticipates a decision on an EYLEA HD prefilled syringe before year-end, which management expects could support further adoption. In metabolic disease, early data for the CIDEB-targeting siRNA showed an approximately 70% reduction in liver fat over 12 weeks, with additional details slated for an upcoming liver meeting. Investors will also follow the expanded Sanofi collaboration announced in October 2026, which includes next-generation long-acting antibodies along with a $1.0 billion upfront payment and up to $7.0 billion in potential milestones. Rising R&D costs, competitive dynamics in ophthalmology, and the timing of pipeline data remain important variables. I’m watching this closely as the company navigates these transitions.
Integrating AI Tools Into Earnings Analysis
In my own workflow, I sometimes use Tickeron’s AI Screener to quickly filter for names with comparable growth profiles or technical setups around earnings season. It helps surface broader context without replacing the fundamental review of individual reports like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REGN in upward trend: 10-day moving average broke above 50-day moving average on October 26, 2026
The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 58 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 32 of 50 cases over the following month. The odds of a continued upward trend are 64%.
REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +14.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 202 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 65 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.013) is normal, around the industry mean (3.162). P/E Ratio (22.161) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (131.622) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medicines for the treatment of serious medical conditions
Industry Biotechnology
Advertisement